NL-OMON47947已完成不适用
Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? - ImaGelato study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. A patient must meet the inclusion criteria of the GELATO trial (see in
- •attachment the protocol)
- •2. Able to give written informed consent and to comply with the ImaGelato
排除标准
- •1. Contra-indication for 89Zr-atezolizumab PET scan
- •2. Any approved anti-cancer therapy, including chemotherapy or hormonal therapy
- •within *14 days prior to the first 89Zr-atezolizumab injection. Treatment with
- •any other investigational agent or participation in another clinical trial with
- •therapeutic intent within 28 days prior to the first 89Zr-atezolizumab
研究者
相似试验
进行中（未招募）
1 期
Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition?obular metastatic breast cancerEUCTR2019-001197-28-NLniversity Medical Center Groningen10
终止
不适用
89Zr-atezolizumab PET Scan and Lobular Breast CancerLobular Metastatic Breast CancerNCT04222426University Medical Center Groningen1
已完成
不适用
89Zr-pembrolizumab-PET imaging in patients with locally advanced or metastatic melanoma or non-small cell lung cancerMelanoma and non-small cell lung cancer1004090010029107NL-OMON43013niversitair Medisch Centrum Groningen21
已完成
不适用
89Zr-bevacizumab labelled PET imaging in patients with Renal Cell Carcinoma treated with sunitinib or bevacizumab plus interferon; a pilot studyNL-OMON33835niversitair Medisch Centrum Groningen26
进行中（未招募）
1 期
Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLETsarcoidosisEUCTR2006-001816-56-DKRigshospitalet10